A new generation of drug-eluting stents: Indications and outcomes of bioresorbable vascular scaffolds. [Review]
Citation: Cleveland Clinic Journal of Medicine. 84(12 Suppl 4):e20-e24, 2017 DecPMID: 29281608Institution: MedStar Heart & Vascular InstituteonForm of publication: Journal ArticleMedline article type(s): Journal Article | ReviewSubject headings: *Absorbable Implants | *Coronary Artery Disease/su [Surgery] | *Coronary Restenosis/pc [Prevention & Control] | *Drug-Eluting Stents | *Percutaneous Coronary Intervention | *Tissue Scaffolds | Coronary Restenosis/et [Etiology] | Drug-Eluting Stents/ae [Adverse Effects] | Drug-Eluting Stents/cl [Classification] | Humans | Percutaneous Coronary Intervention/ae [Adverse Effects] | Percutaneous Coronary Intervention/is [Instrumentation] | Percutaneous Coronary Intervention/mt [Methods] | Treatment OutcomeYear: 2017Local holdings: Available online through MWHC library: 2001- 2010, Available in print through MWHC library: 2002 - presentISSN:- 0891-1150
Item type | Current library | Collection | Call number | Status | Date due | Barcode |
---|---|---|---|---|---|---|
Journal Article | MedStar Authors Catalog | Article | 29281608 | Available | 29281608 |
Available online through MWHC library: 2001- 2010, Available in print through MWHC library: 2002 - present
Drug-eluting stents (DES) are increasingly being used as a less invasive alternative to coronary artery bypass grafting. Early generation DES had durable polymers that provided acceptable efficacy outcomes but had high rates of stent thrombosis leading to myocardial infarction and death. Second-generation DES have improved outcomes by reducing stent thrombosis and recurrent stenosis. Newer DES with biodegradable polymers have similar efficacy as second-generation DES, but have higher rates of stent thrombosis. This review compares outcomes of bioresorbable scaffolds and looks at stent technology developments that may improve outcomes. Copyright (c) 2017 Cleveland Clinic.
English